Completed PHASE1 INTERVENTIONAL 2-arm NCT02428400

Safety and Tolerability of TG1050: A Dose-finding Study

A Phase I/IB Randomized, Double-blind, Placebo Controlled, Dose-finding Study to Evaluate Safety, Tolerability of TG1050 Single/Multiple Doses, and Evaluation of TG1050 Immunologic/Antiviral Activity in Patients With Chronic Hep B Infection

Sponsor: Transgene

Conditions Chronic Hepatitis B

Interventions Placebo TG1050

Updated 8 times since 2017 Last updated: Nov 26, 2018 Started: Oct 31, 2015 Primary completion: Nov 30, 2018 Completion: Nov 30, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02428400, this PHASE1 trial focuses on Chronic Hepatitis B and remains completed. Sponsored by Transgene, it has been updated 8 times since 2015, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Dec 2018 — Jan 2021 [monthly]

Completed PHASE1

Status: Recruiting → Completed

▶ Show 3 earlier versions

Nov 2018 — Dec 2018 [monthly]

Recruiting PHASE1
Jun 2018 — Nov 2018 [monthly]

Recruiting PHASE1
Jan 2017 — Jun 2018 [monthly]

Recruiting PHASE1

First recorded

Oct 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Transgene

Data source: Transgene

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Calgary, Canada , Edmonton, Canada , Freiburg im Breisgau, Germany , Grenoble, France , Hamburg, Germany , Hanover, Germany , Lyon, France , Mainz, Germany , Montreal, Canada , Nancy, France and 2 more locations